Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Breast Neoplasms 3Vulvar Neoplasms 2Melanoma 2Liver Metastases 2Ulcer 1Skin Neoplasms 1Recurrence 1Rectal Neoplasms 1Pathologic Processes 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Liver Neoplasms 1Head and Neck Neoplasms 1Gynecological Cancers 1Desmoid Tumors 1Colorectal Neoplasms 1Breast Cancer Female 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Electrochemotherapy × Clear all
NCT07404605 2026-02-19

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

Institute of Oncology Ljubljana

Phase NA Recruiting
150 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

European Institute of Oncology

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡